• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·KILITCH.NS
Share

Kilitch Drugs Stocks

₹ 180.01Last Updated 24.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 65.20M

₹ 180.01
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Kilitch Drugs (India) Limited, established in 1978 and based in Mumbai, operates a comprehensive pharmaceutical enterprise involved in the development and distribution of a wide array of medicinal and related products, both within India and for export. Their extensive portfolio includes a broad spectrum of parenteral and nasal formulations, addressing various therapeutic categories such as gastroenterology, anti-inflammatory conditions, epilepsy, malaria, and infections, among others. These are available in diverse formats like ampoules, vials, and dry powder injectables, and feature specialized offerings like iron supplements, metered nasal drops, and proprietary brands such as Klavmox and Onecef. The company also manufactures a variety of oral medications, including tablets, capsules, dry syrups, gripe water, and oral liquids and powders, targeting areas such as antibiotics, anti-diabetics, and cardiovascular health. Beyond traditional pharmaceuticals, Kilitch offers effervescent tablets and powders, exemplified by products like ROIPAR, DUREGRA, ROIVIT, and PH-7, as well as nutritional products such as CELTINE. Their innovative solutions include C-Seal, a topical skin adhesive designed for closing wounds without sutures. Furthermore, their product range extends to cosmetics and herbal remedies, encompassing various oils, lotions, liquids, creams, and pastes for skin, personal, and hair care, alongside herbal supplements for conditions like sore throat, prostate issues, diabetes, obesity, and libido enhancement.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.07.2026 23:27

Dior's owner reported an increase in sales of clothing and handbags for the first time in two years

27.07.2026 22:53

Nvidia formed an AI safety alliance following an accidental hack carried out by OpenAI

27.07.2026 22:30

Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?

27.07.2026 22:13

Plata has appointed the former U.S. ambassador to Russia to its board of directors

27.07.2026 21:56

Bank of America announced the temporary closure of its positions in Kazakh government bonds

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026